Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson Sells 8,000 Shares

Iradimed Corp (NASDAQ:IRMD) VP Brent Johnson sold 8,000 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The stock was sold at an average price of $22.68, for a total value of $181,440.00. Following the sale, the vice president now owns 5,368 shares of the company’s stock, valued at $121,746.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Brent Johnson also recently made the following trade(s):

  • On Monday, July 1st, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.46, for a total value of $20,460.00.
  • On Wednesday, July 3rd, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.16, for a total value of $60,480.00.
  • On Friday, June 28th, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $20.53, for a total value of $41,060.00.
  • On Wednesday, June 26th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.34, for a total value of $20,340.00.
  • On Monday, June 24th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $21.02, for a total value of $21,020.00.
  • On Friday, June 21st, Brent Johnson sold 2,000 shares of Iradimed stock. The stock was sold at an average price of $21.36, for a total value of $42,720.00.
  • On Wednesday, June 19th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.73, for a total value of $62,190.00.
  • On Friday, June 14th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.00, for a total value of $20,000.00.
  • On Monday, June 10th, Brent Johnson sold 1,000 shares of Iradimed stock. The stock was sold at an average price of $20.06, for a total value of $20,060.00.
  • On Wednesday, June 12th, Brent Johnson sold 3,000 shares of Iradimed stock. The stock was sold at an average price of $20.57, for a total value of $61,710.00.

Shares of IRMD traded down $0.22 during midday trading on Wednesday, reaching $23.88. 140,055 shares of the stock were exchanged, compared to its average volume of 70,890. Iradimed Corp has a 12-month low of $16.68 and a 12-month high of $38.78. The business has a 50 day simple moving average of $19.66. The company has a debt-to-equity ratio of 0.06, a quick ratio of 8.63 and a current ratio of 9.48. The firm has a market cap of $266.43 million, a P/E ratio of 55.53 and a beta of 1.65.

Iradimed (NASDAQ:IRMD) last posted its quarterly earnings results on Tuesday, April 30th. The medical equipment provider reported $0.11 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.11. Iradimed had a return on equity of 13.98% and a net margin of 23.00%. The company had revenue of $8.44 million during the quarter, compared to the consensus estimate of $8.38 million. As a group, sell-side analysts predict that Iradimed Corp will post 0.64 earnings per share for the current year.

Institutional investors and hedge funds have recently bought and sold shares of the company. Cadence Capital Management LLC increased its position in Iradimed by 64.7% in the 1st quarter. Cadence Capital Management LLC now owns 129,955 shares of the medical equipment provider’s stock worth $3,650,000 after buying an additional 51,050 shares during the period. Victory Capital Management Inc. bought a new position in Iradimed in the 1st quarter worth approximately $212,000. Spark Investment Management LLC increased its position in Iradimed by 86.4% in the 1st quarter. Spark Investment Management LLC now owns 56,100 shares of the medical equipment provider’s stock worth $1,575,000 after buying an additional 26,000 shares during the period. Fiera Capital Corp bought a new position in Iradimed in the 1st quarter worth approximately $1,442,000. Finally, RK Capital Management LLC acquired a new stake in shares of Iradimed during the 1st quarter worth approximately $3,648,000. 23.60% of the stock is owned by institutional investors.

A number of equities research analysts have recently weighed in on the company. ValuEngine raised Iradimed from a “sell” rating to a “hold” rating in a research note on Wednesday. BidaskClub downgraded Iradimed from a “buy” rating to a “hold” rating in a research note on Thursday, May 9th. Finally, Zacks Investment Research downgraded Iradimed from a “buy” rating to a “hold” rating in a research note on Wednesday, July 3rd. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $31.50.

About Iradimed

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; and MRI compatible patient vital signs monitoring system.

Featured Story: Penny Stocks

Insider Buying and Selling by Quarter for Iradimed (NASDAQ:IRMD)

Receive News & Ratings for Iradimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iradimed and related companies with MarketBeat.com's FREE daily email newsletter.